miR‑139‑5p enhances cisplatin sensitivity in non‑small cell lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of Homeobox protein Hox‑B2

Du,Hailian; Bao,Ya'nan; Liu,Chunying; Zhong,Anqiao; Niu,Yikai; Tang,Xingping

doi:10.3892/mmr.2020.11743

miR‑139‑5p enhances cisplatin sensitivity in non‑small cell lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of Homeobox protein Hox‑B2

Authors:
- Hailian Du
- Ya'nan Bao
- Chunying Liu
- Anqiao Zhong
- Yikai Niu
- Xingping Tang
View Affiliations

Affiliations: Department of Respiratory Medicine, Weifang Yidu Central Hospital, Weifang, Shandong 262500, P.R. China, Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China, Ultrasonic Department, Anqiu People's Hospital, Anqiu, Shandong 262100, P.R. China
Published online on: December 1, 2020 https://doi.org/10.3892/mmr.2020.11743
Article Number: 104
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development of chemotherapeutic dug resistance hinders the clinical treatment of cancer. MicroRNAs (miRNAs/miRs) have been revealed to serve essential roles in the drug resistance of numerous types of cancer. miR‑139‑5p was previously reported to be associated with cisplatin (DDP) sensitivity in human nasopharyngeal carcinoma cells and colorectal cancer cells. However, the effect and underlying mechanism of miR‑139‑5p in DDP sensitivity in non‑small cell lung cancer (NSCLC) cells has not yet been fully elucidated. In the present study, the expression of miR‑139‑5p and Homeobox protein Hox‑B2 (HOXB2) in NSCLC tissues was examined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting. Subsequently, the effect of miR‑139‑5p on the DDP sensitivity of NSCLC cells in vitro was investigated. Cell proliferation was examined using a Cell Counting Kit‑8 assay. Western blotting was used to evaluate the protein expression of HOXB2, phosphorylated (p)‑PI3K, p‑AKT, caspase‑3 and cleaved‑caspase‑3, and RT‑qPCR was used to evaluate the expression of miR‑139‑5p, and the mRNA expression levels of HOXB2, PI3K, AKT and caspase‑3. The apoptotic rate of the cells was detected using flow cytometry. miR‑139‑5p expression in NSCLC tissues was shown to be significantly lower compared with that in adjacent tissues. Additionally, miR‑139‑5p increased cell apoptosis and inhibited NSCLC cell proliferation induced by DDP in vitro via modulating the PI3K/AKT/caspase‑3 signaling pathway. Furthermore, HOXB2 was identified to be a target of miR‑139‑5p, and miR‑139‑5p was revealed to sensitize NSCLC cells to DDP via the targeting of HOXB2. Taken together, the results of the present study demonstrated that regulating the expression of miR‑139‑5p could provide a novel approach to reverse DDP resistance and increase chemosensitivity in the treatment of NSCLC.

View Figures

View References

1	Zha L, Sobue T, Kitamura T, Kitamura Y, Sawada N, Iwasaki M, Sasazuki S, Yamaji T, Shimazu T and Tsugane S: Changes in smoking Status and mortality from all causes and lung cancer: A longitudinal analysis of a population-based study in Japan. J Epidemiol. 29:11–17. 2019. View Article : Google Scholar
2	Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G, Petrini I, Palmieri G, Berardi R, Zucali P, Ganzinelli M, et al: Relevent trial: Phase II trial of ramucirumab, carboplatin, and paclitaxel in previously untreated thymic carcinoma/B3 thymoma with area of carcinoma. Clin Lung Cancer. 19:e811–e814. 2018. View Article : Google Scholar
3	Yang D, Liu Y, Bai C, Wang X and Powell CA: Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett. 468:82–87. 2020. View Article : Google Scholar
4	Cao M and Chen W: Epidemiology of lung cancer in China. Thorac Cancer. 10:3–7. 2019. View Article : Google Scholar
5	Duma N, Santana-Davila R and Molina JR: Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar
6	Neal RD, Sun F, Emery JD and Callister ME: Lung cancer. BMJ. 365:l17252019. View Article : Google Scholar
7	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar
8	Lee YG, Lee JH, Kim SH, Kim YJ, Lee H, Ahn S, Jang JS, Lee JS and Kim JH: Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study. Lung Cancer. 122:88–93. 2018. View Article : Google Scholar
9	Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, et al: Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer. 122:234–242. 2018. View Article : Google Scholar
10	Yu X, Zhang L and Chen J: Effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: A retrospective study. Open Med (Wars). 13:142–147. 2018. View Article : Google Scholar
11	Makino A, Miyazaki A, Tomoike A, Kimura H, Arimitsu K, Hirata M, Ohmomo Y, Nishii R, Okazawa H, Kiyono Y, et al: PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy. Bioorg Med Chem. 26:1609–1613. 2018. View Article : Google Scholar
12	To KK, Tong CW, Wu M and Cho WC: MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. World J Gastroenterol. 24:2949–2973. 2018. View Article : Google Scholar
13	Migliore C and Giordano S: Resistance to targeted therapies: A role for microRNAs? Trends Mol Med. 19:633–642. 2013. View Article : Google Scholar
14	Cao L, Wan Q, Li F and Tang CE: MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 51:456–461. 2018. View Article : Google Scholar
15	Wang F, Zhao L, Zhang J, Meng Z, Zhou C, Wang G, Liu Y, Li M, Xi J, Niu W, et al: Chemotherapy-induced miR-141/MAP4K4 signaling suppresses progression of colorectal cancer. Biosci Rep. 38:BSR201809782018. View Article : Google Scholar
16	Li Q, Li B, Li Q, Wei S, He Z, Huang X, Wang L, Xia Y, Xu Z, Li Z, et al: Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition. Cell Death Dis. 9:8542018. View Article : Google Scholar
17	Aggarwal P, Challa KR, Rath M, Sunkara P and Nath U: Generation of inducible transgenic lines of arabidopsis transcription factors regulated by microRNAs. Methods Mol Biol. 1830:61–79. 2018. View Article : Google Scholar
18	Bueno MJ and Malumbres M: MicroRNAs and the cell cycle. Biochim Biophys Acta. 1812:592–601. 2011. View Article : Google Scholar
19	Schneider C, Setty M, Holmes AB, Maute RL, Leslie CS, Mussolin L, Rosolen A, Dalla-Favera R and Basso K: MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proc Natl Acad Sci USA. 111:8185–8190. 2014. View Article : Google Scholar
20	Bukhari SI, Vasquez-Rifo A, Gagné D, Paquet ER, Zetka M, Robert C, Masson JY and Simard MJ: The microRNA pathway controls germ cell proliferation and differentiation in C. elegans. Cell Res. 22:1034–1045. 2012. View Article : Google Scholar
21	Zhang Z, Zhang C, Li F, Zhang B and Zhang Y: Regulation of memory CD8⁺ T cell differentiation by microRNAs. Cell Physiol Biochem. 47:2187–2198. 2018. View Article : Google Scholar
22	Fu X, He Y, Wang X, Peng D, Chen X, Li X and Wan Q: MicroRNA-16 promotes ovarian granulosa cell proliferation and suppresses apoptosis through targeting PDCD4 in polycystic ovarian syndrome. Cell Physiol Biochem. 48:670–682. 2018. View Article : Google Scholar
23	Li J, Zhou Q, Liang Y, Pan W, Bei Y, Zhang Y, Wang J and Jiao Z: miR-486 inhibits PM2.5-induced apoptosis and oxidative stress in human lung alveolar epithelial A549 cells. Ann Transl Med. 6:209–218. 2018. View Article : Google Scholar
24	Li H, Feng C and Shi S: miR-196b promotes lung cancer cell migration and invasion through the targeting of GATA6. Oncol Lett. 16:247–252. 2018.
25	Maemura K, Watanabe K, Ando T, Hiyama N, Sakatani T, Amano Y, Kage H, Nakajima J, Yatomi Y, Nagase T, et al: Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. Cancer Sci. 109:3326–3335. 2018. View Article : Google Scholar
26	Ulivi P and Zoli W: miRNAs as non-invasive biomarkers for lung cancer diagnosis. Molecules. 19:8220–8237. 2014. View Article : Google Scholar
27	Yong-Hao Y, Xian-Guo W, Ming X and Jin-Ping Z: Expression and clinical significance of miR-139-5p in non-small cell lung cancer. J Int Med Res. 47:867–874. 2019. View Article : Google Scholar
28	Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y, et al: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 6:39756–39792. 2015. View Article : Google Scholar
29	Wang K, Jin J, Ma T and Zhai H: MiR-139-5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9. J Cell Mol Med. 21:3730–3740. 2017. View Article : Google Scholar
30	Li Q, Liang X, Wang Y, Meng X, Xu Y, Cai S, Wang Z, Liu J and Cai G: miR-139-5p inhibits the epithelial-mesenchymal transition and enhances the chemotherapeutic sensitivity of colorectal cancer cells by downregulating BCL2. Sci Rep. 6:271572016. View Article : Google Scholar
31	Xu W, Hang M, Yuan CY, Wu FL, Chen SB and Xue K: MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer. Int J Clin Exp Pathol. 8:3864–3870. 2015.
32	Clemenceau A, Boucherat O, Landry-Truchon K, Lamontagne M, Biarde S, Joubert P, Gobeil S, Secco B, Laplante M, Morissette M, et al: Lung cancer susceptibility genetic variants modulate HOXB2 expression in the lung. Int J Dev Biol. 62:857–864. 2018. View Article : Google Scholar
33	Liu J, Li S, Cheng X, Du P, Yang Y and Jiang WG: HOXB2 is a putative tumour promoter in human bladder cancer. Anticancer Res. 39:6915–6921. 2019. View Article : Google Scholar
34	Li S, Pei Y, Wang W, Liu F, Zheng K and Zhang X: Circular RNA 0001785 regulates the pathogenesis of osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2. Cell Cycle. 18:1281–1291. 2019. View Article : Google Scholar
35	Lindblad O, Chougule RA, Moharram SA, Kabir NN, Sun J, Kazi JU and Rönnstrand L: The role of HOXB2 and HOXB3 in acute myeloid leukemia. Biochem Biophys Res Commun. 467:742–747. 2015. View Article : Google Scholar
36	Inamura K, Togashi Y, Ninomiya H, Shimoji T, Noda T and Ishikawa Y: HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells. Anticancer Res. 28:2121–2127. 2008.
37	Inamura K, Togashi Y, Okui M, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Shimoji T, Noda T, et al: HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas. J Thorac Oncol. 2:802–807. 2007. View Article : Google Scholar
38	Xiao H, Liu Y, Liang P, Wang B, Tan H, Zhang Y, Gao X and Gao J: TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis. Cell Biosci. 8:232018. View Article : Google Scholar
39	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
40	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife. 4:e050052015. View Article : Google Scholar
41	Guo J, Jin D, Wu Y, Yang L, Du J, Gong K, Chen W, Dai J, Miao S and Xi S: The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine. 35:204–221. 2018. View Article : Google Scholar
42	Hou Z, Xu C, Xie H, Xu H, Zhan P, Yu L and Fang X: Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One. 9:e1081332014. View Article : Google Scholar
43	Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S and Blandino G: MicroRNAs: Short non-coding players in cancer chemoresistance. Mol Cell Ther. 2:162014. View Article : Google Scholar
44	Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, Zhang J, Peng C, Lin Y and Chen J: MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 5:7013–7026. 2014. View Article : Google Scholar
45	Ju J: Implications of miRNAs in colorectal cancer chemoresistance. Int Drug Discov. 2011:20112011.
46	Wang XH, Lu H, Li TS, Yu Y, Liu G, Peng X and Zhao JH: KLF8 induces breast stemness and chemoresistance via miRNAs associated with EMT. Mol Cancer Ther. 12:A100. 2013.
47	Carta A, Chetcuti R and Ayers D: An introspective update on the influence of miRNAs in breast carcinoma and neuroblastoma chemoresistance. Genet Res Int. 2014:7430502014.
48	Shen K, Mao R, Ma L, Li Y, Qiu Y, Cui D, Le V, Yin P, Ni L and Liu J: Post-transcriptional regulation of the tumor suppressor miR-139-5p and a network of miR-139-5p-mediated mRNA interactions in colorectal cancer. FEBS J. 281:3609–3624. 2014. View Article : Google Scholar
49	Chen Y, Cao XY, Li YN, Qiu YY, Li YN, Li W and Wang H: Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer. Am J Physiol Cell Physiol. 315:C225–C235. 2018. View Article : Google Scholar
50	Ni H, Dai X, Leng X, Deng M, Qin Y, Ji Q, Xu C, Li J and Liu Y: Higher variety and quantity of microRNA-139-5p isoforms confer suppressive role in hepatocellular carcinoma. J Cell Biochem. 119:6806–6813. 2018. View Article : Google Scholar
51	Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun H, Jiang Y, Zhang W, Liang A, Guo Y, et al: miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. Tumour Biol. 36:6741–6749. 2015. View Article : Google Scholar
52	Hua S, Lei L, Deng L, Weng X, Liu C, Qi X, Wang S, Zhang D, Zou X, Cao C, et al: miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1. Oncogene. 37:1624–1636. 2018. View Article : Google Scholar
53	Liu H, Yin Y, Hu Y, Feng Y, Bian Z, Yao S, Li M, You Q and Huang Z: miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. Pathol Res Pract. 212:643–649. 2016. View Article : Google Scholar
54	Pajic M, Froio D, Daly S, Doculara L, Millar E, Graham PH, Drury A, Steinmann A, de Bock CE, Boulghourjian A, et al: miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Res. 78:501–515. 2018. View Article : Google Scholar
55	Boimel PJ, Cruz C and Segall JE: A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer. Genomics. 98:164–172. 2011. View Article : Google Scholar
56	Wang Y, Wang H, Song T, Zou Y, Jiang J, Fang L and Li P: HOTAIR is a potential target for the treatment of cisplatin resistant ovarian cancer. Mol Med Rep. 12:2211–2216. 2015. View Article : Google Scholar
57	Sellar GC, Watt KP, Li L, Nelkin BD, Rabiasz GJ, Porteous DJ, Smyth JF and Gabra H: The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer. Int J Oncol. 21:929–933. 2002.
58	Gonzalez-Herrera A, Salgado-Bernabe M, Velazquez-Velazquez C, Salcedo-Vargas M, Andrade-Manzano A, Avila-Moreno F and Pina-Sanchez P: Increased expression of HOXB2 and HOXB13 proteins is associated with HPV infection and cervical cancer progression. Asian Pac J Cancer Prev. 16:1349–1353. 2015. View Article : Google Scholar
59	Liu J, Li C, Jiang Y, Wan Y, Zhou S and Cheng W: Tumor-suppressor role of miR-139-5p in endometrial cancer. Cancer Cell Int. 18:512018. View Article : Google Scholar
60	Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 1855:104–121. 2015.
61	Catanzaro G, Besharat ZM, Miele E, Chiacchiarini M, Po A, Carai A, Marras CE, Antonelli M, Badiali M, Raso A, et al: The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling. Neuropathol Appl Neurobiol. 44:687–706. 2018. View Article : Google Scholar
62	Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M, Huang P and Yu D: Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res. 26:564–572. 2014.
63	Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, Jin Y and Wu Y: miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 35:1287–1295. 2014. View Article : Google Scholar
64	Chen J, Lan T, Zhang W, Dong L, Kang N, Fu M, Liu B, Liu K, Zhang C, Hou J, et al: Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways. Arch Biochem Biophys. 575:38–45. 2015. View Article : Google Scholar